NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy
A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.
Expert Perspectives on Molecular Testing in Non–Small Cell Lung Cancer
Comprehensive discussion on molecular testing strategies utilized in non–small cell lung cancer to help inform treatment decisions.
Case 1: Frontline Treatment of ALK+ NSCLC With Brain Metastases
Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.
Overview on ALK+ Metastatic Non–Small Cell Lung Cancer
Expert panelists open their discussion on ALK+ non–small cell lung cancer and reflect on the impact of CNS metastasis in this setting.
2 Clarke Drive Cranbury, NJ 08512